Trial Profile
Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule(s) and Dose(s) of Melphalan for Injection (Evomela) as a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 16 Jan 2024
Price :
$35
*
At a glance
- Drugs Melphalan (Primary) ; Filgrastim; Palifermin
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacokinetics
- 12 Dec 2023 Results assessing the dose escalation and compared the short versus extended infusion time of evomela used as a conditioning regimen before auto-HCT, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 26 Oct 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 26 Oct 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.